Latent TB Testing Market to Surge With 5.7% CAGR Global Revenue to Exceed US$ 1,005.69 Million Forecast by 2025 to 2034

The global latent TB testing market was estimated to be worth USD 576.68 million in 2024. It is forecast to grow to USD 1,005.69 million by 2034, with a CAGR of 5.7% during the forecast period, 2025 to 2034.

Market Explanation:
Latent TB infection signifies that TB germs are prevalent in the body, but they are dormant. They are not detrimental to the person and do not spread to other people. If the TB germs rouse and become active, they can make the person fall ill. Consuming medicines for latent TB assists in prohibiting latent TB germs from rousing and causing active TB illness. The low tissue bacterial load linked with LTBI resists any diagnostic procedure focused on the identification of the bacteria or its constituents.

Get Exclusive Sample Pages of This Report:
https://www.polarismarketresearch.com/industry-analysis/latent-tb-testing-market/request-for-sample

The TB diagnostics method is somewhat secondary and depends on the proof of a cellular immune response to mycobacterial antigens. The normal tests include the intradermal tuberculin test (TST) and interferon-gamma release assay (IGRA). Treatment can last up to three, four, six, or nine months, depending on the instruction. Drugs such as Isoniazid (H), Rifapentine (P), and Rifampin (R) are recommended for the cure of latent TB.

Market Drivers:
Growing Funding for TB Control Programs:
Government bodies, worldwide health firms, and private structures issue notable financial resources to fight tuberculosis, with a robust concentration on pre-mature detection and prohibition. In September 2024, the Global Fund announced offering 76% of international TB funding, funding USD 9.9 billion in TB prohibition and treatment programs and an extra USD 1.9 billion in TB/HIV enterprise as of June 2024, reinforcing global endeavors to fight tuberculosis, thus driving the latent TB testing market growth.

Rising Cases of TB:
The growing cases of latent TB are driving the demand for the market as the growing aggregate of persons sustains the contamination without portraying signs. For instance, in May 2024, the CDC approximated that up to 13 million people in the US have latent TB contamination.

Key Contenders:
The firms focus on capturing the market by improving their existence using several business enterprises such as alliances and partnerships with the government.

Some of the prominent players operating in the market include:
• Abbott Laboratories
• AID Autoimmun Diagnostika GmbH
• ARKRAY, Inc.
• Beijing Wantai Biopharmaceutical Co., Ltd.
• bioMérieux
• Boditech Med Inc.
• Endo, Inc.
• Lionex GmbH
• Oxford Immunotec (PerkinElmer)
• QIAGEN
• Revvity
• Sanofi
• SD Biosensor, INC.
• Serum Institute of India Pvt. Ltd.
• Zhi Fei Biological

Request for a Discount on this Report Before Purchase:
https://www.polarismarketresearch.com/industry-analysis/latent-tb-testing-market/request-for-discount-pricing

Latent TB Testing Market Report Highlights:
• In terms of test type, the IGRA segment dominated the latent TB testing market share in 2024, due to its higher accuracy, reliability, and efficiency compared to the traditional Tuberculin Skin Test (TST).

• Based on end user, the hospitals and clinics segment is expected to witness the fastest growth, driven by their role as primary providers for routine screenings and diagnostic services.

• North America dominated the latent TB testing market revenue in 2024, supported by robust healthcare infrastructure, high awareness, and extensive screening programs.

• The Asia Pacific market is projected to experience the fastest market growth, fueled by the rising TB burden and increasing focus on early detection strategies.

Market Segmentation:
The latent TB testing market segmentation is done on the basis of test type, application, end user, and region.
Based on test type, the IGRA segment dominated the market in 2024 due to its better preciseness, dependability, and productivity as contrasted to the conventional Tuberculin Skin Test (TST).

Based on end user, the hospitals & clinics segment is anticipated to witness the fastest growth due to their part as a primary healthcare provider for patterned tuberculosis screening.

By Test Type Outlook (Volume, Number of Tests in Thousands; Revenue, USD Million, 2020-2034)
• IGRA
• TST

By Application Outlook (Volume, Number of Tests in Thousands; Revenue, USD Million, 2020-2034)
• People Living with HIV
• HHC with TB
• Others

By End User Outlook (Volume, Number of Tests in Thousands; Revenue, USD Million, 2020-2034)
• Diagnostic Laboratories
• Hospitals & Clinics
• Academic & Research Institutes
• Others

Explore The Complete Comprehensive Report Here:
https://www.polarismarketresearch.com/industry-analysis/latent-tb-testing-market

Geographical Analysis:
• North America
o US
o Canada

• Europe
o Germany
o UK
o France
o Italy
o Spain
o Russia
o Netherlands
o Rest of Europe

• Asia Pacific
o China
o India
o Japan
o South Korea
o Indonesia
o Malaysia
o Vietnam
o Australia
o Rest of Asia Pacific

• Latin America
o Argentina
o Brazil
o Mexico
o Rest of Latin America

• Middle East & Africa
o UAE
o Saudi Arabia
o Israel
o South Africa
o Rest of Middle East & Africa

More Trending Latest Reports by Polaris Market Research:
Remote Surgery Technology Platforms Market:
https://www.polarismarketresearch.com/industry-analysis/remote-surgery-technology-platforms-market

Brain Monitoring Market:
https://www.polarismarketresearch.com/industry-analysis/brain-monitoring-market

Medical Lasers Market:
https://www.polarismarketresearch.com/industry-analysis/medical-lasers-market

Healthcare Supply Chain Management Market:
https://www.polarismarketresearch.com/industry-analysis/healthcare-supply-chain-management-market

Contact:
Likhil G
8 The Green Ste 19824,
Dover, DE 19901,
United States
Phone: +1-929 297-9727
Email: sales@polarismarketresearch.com
Web: https://www.polarismarketresearch.com
Follow Us: LinkedIn | Twitter

About Polaris Market Research & Consulting, Inc:
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR's clientele spread across different enterprises. We at Polaris are obliged to serve PMR's diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR's customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR's customers.

This release was published on openPR.